Key Points
- Bernard Coulie sold 89,375 shares on Jan. 20 at an average of $1.28 for $114,400, reducing his stake by 15.02% to 505,601 shares (valued at about $647,169).
- PLRX opened at $1.30 (50‑day/200‑day averages $1.35/$1.50), has a market cap of roughly $79.9 million and a one‑year range of $1.10–$12.88, while analysts' consensus rating is "Reduce" with a $3.93 price target.
- Pliant is a clinical‑stage biopharma developing integrin inhibitor PLN‑74809 for fibrotic diseases, and institutional investors own about 97.3% of the company’s stock.
Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) CEO Bernard Coulie sold 89,375 shares of the stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $1.28, for a total value of $114,400.00. Following the transaction, the chief executive officer directly owned 505,601 shares of the company's stock, valued at approximately $647,169.28. This trade represents a 15.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Pliant Therapeutics Stock Performance
Shares of PLRX opened at $1.30 on Friday. The stock's fifty day moving average price is $1.35 and its two-hundred day moving average price is $1.50. Pliant Therapeutics, Inc. has a 1 year low of $1.10 and a 1 year high of $12.88. The firm has a market cap of $79.89 million, a PE ratio of -0.45 and a beta of 1.36. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.94 and a quick ratio of 13.93.
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.10. On average, equities research analysts forecast that Pliant Therapeutics, Inc. will post -3.64 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of Pliant Therapeutics in a research report on Friday, October 10th. Wall Street Zen upgraded Pliant Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, November 16th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Pliant Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Pliant Therapeutics presently has an average rating of "Reduce" and a consensus price target of $3.93.
Check Out Our Latest Research Report on Pliant Therapeutics
Hedge Funds Weigh In On Pliant Therapeutics
A number of institutional investors have recently made changes to their positions in the stock. Invesco Ltd. grew its position in Pliant Therapeutics by 42.2% in the first quarter. Invesco Ltd. now owns 68,963 shares of the company's stock worth $93,000 after acquiring an additional 20,449 shares in the last quarter. Royal Bank of Canada lifted its stake in Pliant Therapeutics by 222.4% during the first quarter. Royal Bank of Canada now owns 362,702 shares of the company's stock worth $491,000 after purchasing an additional 250,185 shares during the last quarter. AQR Capital Management LLC purchased a new position in shares of Pliant Therapeutics in the 1st quarter worth about $97,000. Goldman Sachs Group Inc. increased its position in shares of Pliant Therapeutics by 6.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 475,877 shares of the company's stock valued at $642,000 after purchasing an additional 29,177 shares during the last quarter. Finally, Woodline Partners LP increased its position in shares of Pliant Therapeutics by 1,875.0% during the 1st quarter. Woodline Partners LP now owns 2,514,084 shares of the company's stock valued at $3,394,000 after purchasing an additional 2,386,789 shares during the last quarter. Institutional investors own 97.30% of the company's stock.
Pliant Therapeutics Company Profile
(
Get Free Report)
Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.
The company's lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
